Goodbye, Watson Pharmaceuticals -- Hello, Actavis

Before you go, we thought you'd like these...
Before you go close icon

Investors may have been surprised today to find that the ticker symbol for Watson Pharmaceuticals, a well-known stalwart of the generic pharmaceutical industry, is now defunct. However, there's no need to panic: The company has simply changed its name to Actavis . Our health-care analyst Max Macaluso goes into the details behind the rebranding in this video.

Editor's note: One look at the statistics box that enters the video at 19 seconds reveals the timeliness of this report -- this ticker is so new that the company's information hasn't yet been added to our database! The information listed there is incorrect, and the Fool regrets the error. 


While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Goodbye, Watson Pharmaceuticals -- Hello, Actavis originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners